431:
work was completed. Under the terms of the agreement, Compugen received $ 10 million up front payment and was set to receive $ 30 million, plus up to $ 500 million in milestone payments on both programs and was eligible for mid to high single-digit royalties on product sales. In 2017, after joint assessment of the CGEN-15022 program, the investment in the program was halted and the Bayer collaboration shifted solely CGEN-15001T. To date, Compugen received approximately $ 25 million in up front and preclinical milestone payments and is eligible to up to $ 250 million in milestone payments and mid to high single-digit royalties on product sales. In April 2018, Bayer disclosed the target of this program as ILDR2 and announced its intention to advance the program to the clinic.
418:. Under the terms of the agreement, Bristol Bristol-Myers Squibb will supply Opdivo®, its PD-1 inhibitor, for the combination arm of Compugen's Phase 1 study designed to evaluate the safety and tolerability of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast, and endometrial cancer. In addition, Bristol-Myers may initiate and fund clinical trials that assess combinations of multiple checkpoint inhibitors, including PVRIG (the target of COM701), and TIGIT. In conjunction with the collaboration agreement, Bristo-Mayers Squibb made a $ 12 million equity investment in Compugen, holding approximately 4% of the company.
443:, the global biologics research arm of AstraZeneca to develop bi-specific and multi-specific immuno-oncology antibody products derived from one of Compugen's pipeline products. MedImmune has the right to develop multiple product under this license and is solely responsible for R&D and commercial expenses. Under the terms of the agreement, Compugen will receive a $ 10 million upfront payment and up to $ 200 million in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If any other products are developed, Compugen is eligible for additional milestone payments and royalties.
384:. BAY 1905254, an antibody targeting ILDR2 was co-developed by Compugen and Bayer. After completing preclinical development, the program was transferred to Bayer for further development. Under the terms of their license and collaboration agreement, Bayer is responsible for all the clinical development of BAY 1905254 and its future commercialization worldwide, if the therapy is approved. In September 2018, Bayer initiated patient dosing in a Phase 1 trial assessing the safety and tolerability of BAY 1905254. The study is currently recruiting in patients in the United States. The trial will include 196 patients.
1303:
372:
safety and tolerability of COM701 as monotherapy and in combination with a PD-1 inhibitor. Additional endpoints include evaluation of PK/PD and preliminary clinical activity in certain tumor types such as NSCLC, breast, ovarian endometrial cancer. Preclinical data demonstrate that these tumor types express a high level of the biomarkers PVRIG and PVRL2. The Phase 1 study is currently enrolling at various sites in the United States.
1292:
212:
190:
165:
455:, (JHU) on immune checkpoint candidates for the potential treatment of cancer. This collaborative research expanded Compugen's ongoing assessment of the biology and mechanism of action of its novel B7/CD8-like immune checkpoint proteins, and provided access to the world-class I-O research tools and expertise at JHU. The project is overseen by Prof.
278:. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as
459:
and Dr. Charles Drake, members of
Compugen's scientific advisory board and well-known pioneers in the field of immuno-oncology. In October 2017, the collaboration was expanded to include new additional targets discovered by Compugen which have the potential to serve as a basis for the development of
430:
to develop antibody drugs for cancer immunotherapy against two
Compugen-discovered immune checkpoint regulators CGEN-15001T and CGEN-15022. The companies agreed to collaborate on preclinical programs, with Bayer retaining full control over clinical development and commercialization after preclinical
371:
PVRIG is a novel B7/CD28-like immune checkpoint target candidate. In June 2016, Compugen announced the selection of COM701 as the lead therapeutic candidate for PVRIG. COM701 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors. The study is designed to evaluate the
468:
In
November 2017, Compugen announced a multi-year research collaboration with Mount Sinai Hospital, under the direction of Dr. Miriam Merad. The collaboration focuses on the research and target validation of selected myeloid candidates discovered by Compugen for their potential to serve as a basis
338:
clustering and assembly platform. By around 2001, Compugen had effected a shift in its business model from a company whose almost exclusive focus was marketing computer programs and applications to one whose operations extended into the diagnostics and therapeutics fields. In 2010, under Dr.
392:
TIGIT is an immune checkpoint in the B7/CD28 family. In March 2017, COM902 was selected as the lead therapeutic candidate for CGEN-15137/TIGIT. Compugen is planning to file an IND with the FDA and initiate a Phase 1 study for COM902 in 2019.
330:
to develop a more powerful specialized processor for sequence similarity searches; and the company's first product, dubbed the "Bioccelerator", had speeds up to one thousand times faster than other platforms being used at the time.
1258:
1678:
931:
FierceBiotech, Bristol-Myers, Compugen ally to test checkpoint combinations, October 11, 2018, and Globes, BMS invests $ 12m in
Compugen for tumor collaboration, October 11, 2018
63:
1153:
976:
Script, Compugen
Concentrates on Pipeline After AZ Antibody Pact, April 3, 2018 and Globes, Compugen Signs Cancer Drug Licensing Deal Worth up to $ 200M, April 2, 2018
310:
Compugen was founded by Eli Mintz, Simchon
Faigler and Amir Natan. Mintz conceived of the idea for the company in 1991 while accompanying his wife, Liat Mintz, to a
518:
452:
1683:
380:
ILDR2 (internal designation CGEN-15001T) is a novel B7/CD28-like immune checkpoint target candidate discovered by
Compugen. This program is partnered to
1698:
1280:
290:. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on
1693:
1688:
878:
339:
Cogen-Dayag's new leadership, the company shifted its business model to become a fully integrated biopharma company using its developed
715:
Xie, Hanqing; Gill-More, Raveh (2004). "Transcriptome
Analysis Through Expressed Sequences". In Seckbach, Joseph; Rubin, Eitan (eds.).
182:
1120:
1703:
1647:
1523:
1473:
734:
609:
469:
for cancer immunotherapy treatments, including the validation of their role in innate immunity and involvement in tumor biology.
1088:
27:
597:
1468:
1427:
1157:
1229:"President & CEO of Compugen Ltd. talks about potential long-term large revenues from licensing of in-house discoveries"
322:
exceeded what computers could process at reasonable speeds. Eli Mintz partnered with colleagues
Faigler and Natan from the
922:
Immuno-Oncology News, Bayer Begins Phase 1 Trial of BAY 1905254 Immunotherapy for
Advanced Solid Cancers, October 12, 2018
807:לדבריו, החברה מעוניינת לזהות את ההזדמנויות ולהיות שותפה בתחומי הדיאגנוסטיקה והתרפויטיקה, לא רק למכור תוכנות ואפליקציות.
1273:
145:
851:
1610:
1559:
1498:
1478:
1417:
1334:
1232:
726:
633:
346:
Compugen began trading on the Nasdaq in 2000 and on the Tel Aviv Stock Exchange in 2002. Also in 2002, Compugen
1412:
1250:
299:
601:
478:
275:
149:
59:
1266:
1219:
335:
481:
and president from 1998 to 2005. He was replaced by Alex Kotzer, who was CEO and president through 2008.
1463:
340:
323:
271:
967:
Bayer press release, Bayer to showcase data from diverse oncology pipeline at AACR 2018, April 5, 2018
913:
Seeking Alpha, Compugen's first patient dosed with COM701 in Phase 1 clinical trial, September 7, 2018
343:
discovery technology to identify novel targets and develop its own pipeline of immuno-oncology drugs.
1631:
1382:
498:
415:
291:
168:
1066:
828:
1590:
1574:
283:
414:
In October 2018, Compugen announced a clinical collaboration and equity investment agreement with
1605:
1019:
763:
680:מערכת המחשב שפותחה היתה מסוגלת לבצע השוואות של רצפים גנטיים במהירות של עד פי 1,000 ממערכות אחרות.
347:
1014:
758:
451:
In December 2014, Compugen announced the initiation of a multi-year research collaboration with
985:
Israel 21c, Compugen teams with Johns Hopkins University on immune checkpoints, January 1, 2015
730:
605:
318:
in France. She commented that the quantities of data being produced by scientists involved in
315:
1182:
564:
1615:
1442:
1422:
1397:
1359:
888:
513:
482:
141:
1130:
1041:
693:
1364:
883:
327:
255:
1199:
1554:
1528:
1513:
1344:
940:
BioWorld Today, Compugen Rockets on $ 540M Bayer Immunotherapy Alliance, August 6, 2013
554:
BioWorld Today, Compugen Rockets on $ 540M Bayer Immunotherapy Alliance, August 6, 2013
486:
319:
263:
37:
1098:
1672:
1652:
1595:
1339:
1302:
892:
508:
73:
55:
45:
879:"Evogene, a Subsidiary of Compugen, Raising U.S. $ 2.0 Million in Private Financing"
1508:
456:
1228:
716:
591:
426:
In August 2013, Compugen entered into a collaboration and license agreement with
949:
Bioworld Today, Compugen flexes dealmaking muscle in Medimmune I-O antibody pact
568:
355:
1549:
1432:
1392:
1349:
1093:
204:
1569:
1437:
1407:
1323:
793:
722:
503:
440:
401:
CGEN-15001/ILDR2-Fc is the company's lead program for autoimmune diseases.
26:
786:
545:
Spotlight on Israel: Compugen Comes Forth, Script Magazine, April 24, 2018
1564:
1503:
1488:
1483:
1447:
1387:
1328:
818:
Globes, ד"ר ענת כהן-דייג מספרת איך החזירה את קומפיוג'ן מהתהום ,22.11.2015
659:
439:
In March 2018, Compugen entered into an exclusive license agreement with
427:
381:
311:
279:
135:
1657:
1533:
1518:
1402:
1318:
856:
666:
590:
Khavul, Susanna (2005). "Chapter 4: Israel". In Simon Commander (ed.).
351:
295:
1600:
1493:
1354:
1297:
1291:
1204:
1190:
1125:
287:
267:
51:
1214:
334:
In 1997, the company followed this success by introducing LEADS, an
114:
1262:
477:
Mor Amitai, who joined Compugen in 1994, was the company's
1154:"Martin Gerstel's back in business, this time in Israel"
791:[Compugen transitions to development of drugs].
1015:"Compugen to Raise $ 55 Mln at $ 280 Mln Value Tonight"
489:. She has been the company's exclusive CEO since 2010.
485:
became co-CEO of Compugen in 2009, serving alongside
1640:
1624:
1583:
1542:
1456:
1373:
1311:
1003:
DDNews, Compugen and JHU chart new course, May 2015
994:
DDNews, Compugen and JHU chart new course, May 2015
224:
202:
180:
159:
125:
109:
97:
79:
69:
43:
33:
1067:"COMPUGEN LTD, Form 6-K, Filing Date Aug 20, 2008"
229:
1042:"COMPUGEN LTD, Form 6-K, Filing Date Jul 2, 2003"
262:) is a clinical-stage publicly traded predictive
1679:Companies listed on the Tel Aviv Stock Exchange
634:"Computing the benefits of genes and proteins"
519:List of Israeli companies quoted on the Nasdaq
1274:
1215:"Israeli Army Grads Lead Business Revolution"
958:Compugen, Annual Report, filed March 27, 2018
565:"Compugen Ltd: Company profile from Hoover's"
8:
19:
453:Johns Hopkins University School of Medicine
447:Johns Hopkins University School of Medicine
1281:
1267:
1259:
25:
18:
593:The Software Industry in Emerging Markets
266:and development company headquartered in
1152:London Sappir, Shoshana (4 March 2002).
1121:"Anat Cohen Dayag Profile – Forbes.com"
529:
632:Blackburn, Nicky (12 November 2001).
435:Medimmune (subsidiary of AstraZeneca)
7:
1213:Rosenberg, David (September 2000).
259:
694:"Compugen Transforms Its Business"
302:are among Compugen's competitors.
14:
1684:Biotechnology companies of Israel
1648:Ampal-American Israel Corporation
1524:Sapiens International Corporation
1474:Check Point Software Technologies
1198:Pitta, Julie (23 February 1998).
757:Pincas, Gitit (1 November 2004).
718:The New Avenues in Bioinformatics
692:Russell, John (17 October 2005).
460:cancer immunotherapy treatments.
1301:
1290:
1193:: PR Editions. 25 February 2010.
1183:"Compugen hits gold with Pfizer"
1013:Tsipori, Tali (13 August 2000).
664:[Compugen's evolution].
211:
210:
189:
188:
164:
163:
850:Coren, Ora (18 February 2004).
658:Ginzburg, Ami (3 August 2001).
598:Gloucestershire, United Kingdom
240:Footnotes / references
1699:Companies listed on the Nasdaq
1469:B.O.S. Better Online Solutions
1428:Partner Communications Company
1:
1694:1993 establishments in Israel
1689:Companies established in 1993
852:"Propagating the Evogene way"
788:קומפיוג'ן עוברת לפיתוח תרופות
16:Israeli biotechnology company
1296:Israeli companies traded on
1246:Business data for Compugen:
661:תהליך האבולוציה של קומפיוג'ן
270:, with shares traded on the
1601:Ituran Location and Control
1156:. Israel21c. Archived from
536:Compugen 2016 Annual Report
405:Partnerships/collaborations
85:; 31 years ago
1720:
1611:RADA Electronic Industries
1560:Nova Measuring Instruments
1499:Magic Software Enterprises
1479:ClickSoftware Technologies
1418:Internet Gold Golden Lines
1233:The Wall Street Transcript
829:"Compugen Company Profile"
759:"Compugen's metamorphosis"
727:Kluwer Academic Publishers
397:CGEN-15001/ILDR2 Fc Fusion
785:Coren, Ora (4 May 2001).
238:
24:
1704:Drug discovery companies
1413:Gilat Satellite Networks
787:
660:
602:Edward Elgar Publishing
300:Five Prime Therapeutics
296:OncoMed Pharmaceuticals
276:Tel Aviv Stock Exchange
1584:Security & defense
1464:BluePhoenix Solutions
1423:Orckit Communications
1089:"Alex Kotzer Profile"
341:computational biology
272:NASDAQ Capital Market
1632:Caesarstone Sdot-Yam
1383:Allot Communications
604:. pp. 174–175.
499:Human Genome Project
464:Mount Sinai Hospital
416:Bristol-Myers Squibb
410:Bristol-Myers Squibb
354:, established as an
1575:Tower Semiconductor
1374:Communication &
376:BAY 1905254 / ILDR2
21:
1606:Pointer Telocation
1187:Biopharmaceutiques
358:division in 1999.
314:engagement at the
284:Abbot Laboratories
215:US$ -8.5 million
193:US$ -8.7 million
1666:
1665:
1069:. secdatabase.com
1047:. secdatabase.com
696:. Bio-ITWorld.com
316:Pasteur Institute
246:
245:
220:
198:
176:
1711:
1616:TAT Technologies
1443:RiT Technologies
1403:Ceragon Networks
1398:B Communications
1360:Rosetta Genomics
1306:
1305:
1295:
1294:
1283:
1276:
1269:
1260:
1236:
1235:. 30 April 2003.
1224:
1209:
1194:
1170:
1169:
1167:
1165:
1149:
1143:
1142:
1140:
1138:
1129:. Archived from
1117:
1111:
1110:
1108:
1106:
1097:. Archived from
1085:
1079:
1078:
1076:
1074:
1063:
1057:
1056:
1054:
1052:
1046:
1038:
1032:
1031:
1029:
1027:
1010:
1004:
1001:
995:
992:
986:
983:
977:
974:
968:
965:
959:
956:
950:
947:
941:
938:
932:
929:
923:
920:
914:
911:
905:
904:
902:
900:
895:. 6 January 2003
889:Tel Aviv, Israel
875:
869:
868:
866:
864:
847:
841:
840:
838:
836:
825:
819:
816:
810:
809:
804:
802:
782:
776:
775:
773:
771:
754:
748:
747:
745:
743:
712:
706:
705:
703:
701:
689:
683:
682:
677:
675:
655:
649:
648:
646:
644:
629:
623:
622:
620:
618:
587:
581:
580:
578:
576:
561:
555:
552:
546:
543:
537:
534:
514:Genesis Partners
483:Anat Cohen-Dayag
422:Bayer Healthcare
294:and immunology.
261:
234:
231:
216:
214:
213:
194:
192:
191:
183:Operating income
172:
167:
166:
142:Anat Cohen-Dayag
93:
91:
86:
29:
22:
1719:
1718:
1714:
1713:
1712:
1710:
1709:
1708:
1669:
1668:
1667:
1662:
1636:
1620:
1579:
1538:
1452:
1375:
1369:
1365:Syneron Medical
1355:Rewalk Robotics
1307:
1300:
1289:
1287:
1255:
1243:
1227:
1212:
1197:
1181:
1178:
1176:Further reading
1173:
1163:
1161:
1160:on 4 April 2011
1151:
1150:
1146:
1136:
1134:
1133:on 11 June 2011
1119:
1118:
1114:
1104:
1102:
1101:on 11 June 2011
1087:
1086:
1082:
1072:
1070:
1065:
1064:
1060:
1050:
1048:
1044:
1040:
1039:
1035:
1025:
1023:
1012:
1011:
1007:
1002:
998:
993:
989:
984:
980:
975:
971:
966:
962:
957:
953:
948:
944:
939:
935:
930:
926:
921:
917:
912:
908:
898:
896:
884:AllBusiness.com
877:
876:
872:
862:
860:
849:
848:
844:
834:
832:
827:
826:
822:
817:
813:
800:
798:
789:
784:
783:
779:
769:
767:
756:
755:
751:
741:
739:
737:
729:. p. 153.
714:
713:
709:
699:
697:
691:
690:
686:
673:
671:
662:
657:
656:
652:
642:
640:
631:
630:
626:
616:
614:
612:
589:
588:
584:
574:
572:
563:
562:
558:
553:
549:
544:
540:
535:
531:
527:
495:
475:
466:
449:
437:
424:
412:
407:
399:
390:
378:
369:
364:
350:its subsidiary
328:Talpiot program
308:
242:
228:
207:
185:
155:
128:
121:
117:
104:
103:Simchon Faigler
102:
89:
87:
84:
58:
48:
17:
12:
11:
5:
1717:
1715:
1707:
1706:
1701:
1696:
1691:
1686:
1681:
1671:
1670:
1664:
1663:
1661:
1660:
1655:
1650:
1644:
1642:
1638:
1637:
1635:
1634:
1628:
1626:
1625:Consumer goods
1622:
1621:
1619:
1618:
1613:
1608:
1603:
1598:
1593:
1587:
1585:
1581:
1580:
1578:
1577:
1572:
1567:
1562:
1557:
1555:Kornit Digital
1552:
1546:
1544:
1540:
1539:
1537:
1536:
1531:
1529:Verint Systems
1526:
1521:
1516:
1514:Perion Network
1511:
1506:
1501:
1496:
1491:
1486:
1481:
1476:
1471:
1466:
1460:
1458:
1454:
1453:
1451:
1450:
1445:
1440:
1435:
1430:
1425:
1420:
1415:
1410:
1405:
1400:
1395:
1390:
1385:
1379:
1377:
1371:
1370:
1368:
1367:
1362:
1357:
1352:
1347:
1345:Mazor Robotics
1342:
1337:
1332:
1331:Pharmaceutical
1326:
1321:
1315:
1313:
1309:
1308:
1288:
1286:
1285:
1278:
1271:
1263:
1257:
1256:
1254:
1253:
1247:
1242:
1241:External links
1239:
1238:
1237:
1225:
1210:
1195:
1177:
1174:
1172:
1171:
1144:
1112:
1080:
1058:
1033:
1005:
996:
987:
978:
969:
960:
951:
942:
933:
924:
915:
906:
870:
842:
831:. BioPortfolio
820:
811:
777:
749:
735:
707:
684:
650:
624:
610:
582:
556:
547:
538:
528:
526:
523:
522:
521:
516:
511:
506:
501:
494:
491:
487:Martin Gerstel
474:
471:
465:
462:
448:
445:
436:
433:
423:
420:
411:
408:
406:
403:
398:
395:
389:
388:COM902 / TIGIT
386:
377:
374:
368:
367:COM701 / PVRIG
365:
363:
360:
320:DNA sequencing
307:
304:
264:drug discovery
244:
243:
236:
235:
226:
222:
221:
208:
203:
200:
199:
186:
181:
178:
177:
161:
157:
156:
154:
153:
139:
131:
129:
126:
123:
122:
119:
113:
111:
107:
106:
99:
95:
94:
81:
77:
76:
71:
67:
66:
49:
44:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1716:
1705:
1702:
1700:
1697:
1695:
1692:
1690:
1687:
1685:
1682:
1680:
1677:
1676:
1674:
1659:
1656:
1654:
1653:Elbit Imaging
1651:
1649:
1646:
1645:
1643:
1641:Conglomerates
1639:
1633:
1630:
1629:
1627:
1623:
1617:
1614:
1612:
1609:
1607:
1604:
1602:
1599:
1597:
1596:Elbit Systems
1594:
1592:
1589:
1588:
1586:
1582:
1576:
1573:
1571:
1568:
1566:
1563:
1561:
1558:
1556:
1553:
1551:
1548:
1547:
1545:
1541:
1535:
1532:
1530:
1527:
1525:
1522:
1520:
1517:
1515:
1512:
1510:
1507:
1505:
1502:
1500:
1497:
1495:
1492:
1490:
1487:
1485:
1482:
1480:
1477:
1475:
1472:
1470:
1467:
1465:
1462:
1461:
1459:
1455:
1449:
1446:
1444:
1441:
1439:
1436:
1434:
1431:
1429:
1426:
1424:
1421:
1419:
1416:
1414:
1411:
1409:
1406:
1404:
1401:
1399:
1396:
1394:
1391:
1389:
1386:
1384:
1381:
1380:
1378:
1372:
1366:
1363:
1361:
1358:
1356:
1353:
1351:
1348:
1346:
1343:
1341:
1340:Given Imaging
1338:
1336:
1333:
1330:
1327:
1325:
1322:
1320:
1317:
1316:
1314:
1310:
1304:
1299:
1293:
1284:
1279:
1277:
1272:
1270:
1265:
1264:
1261:
1252:
1249:
1248:
1245:
1244:
1240:
1234:
1230:
1226:
1222:
1221:
1216:
1211:
1207:
1206:
1201:
1196:
1192:
1188:
1184:
1180:
1179:
1175:
1159:
1155:
1148:
1145:
1132:
1128:
1127:
1122:
1116:
1113:
1100:
1096:
1095:
1090:
1084:
1081:
1068:
1062:
1059:
1043:
1037:
1034:
1022:
1021:
1016:
1009:
1006:
1000:
997:
991:
988:
982:
979:
973:
970:
964:
961:
955:
952:
946:
943:
937:
934:
928:
925:
919:
916:
910:
907:
894:
893:Business Wire
890:
886:
885:
880:
874:
871:
859:
858:
853:
846:
843:
830:
824:
821:
815:
812:
808:
796:
795:
790:
781:
778:
766:
765:
760:
753:
750:
738:
736:1-4020-2639-0
732:
728:
724:
720:
719:
711:
708:
695:
688:
685:
681:
669:
668:
663:
654:
651:
639:
635:
628:
625:
613:
611:1-84542-247-3
607:
603:
599:
595:
594:
586:
583:
570:
566:
560:
557:
551:
548:
542:
539:
533:
530:
524:
520:
517:
515:
512:
510:
509:Transcriptome
507:
505:
502:
500:
497:
496:
492:
490:
488:
484:
480:
472:
470:
463:
461:
458:
454:
446:
444:
442:
434:
432:
429:
421:
419:
417:
409:
404:
402:
396:
394:
387:
385:
383:
375:
373:
366:
361:
359:
357:
353:
349:
344:
342:
337:
332:
329:
325:
321:
317:
313:
305:
303:
301:
297:
293:
289:
285:
281:
277:
273:
269:
265:
257:
253:
250:
241:
237:
233:
227:
223:
219:
209:
206:
201:
197:
187:
184:
179:
175:
170:
162:
158:
151:
147:
143:
140:
137:
134:Paul Sekhri (
133:
132:
130:
124:
116:
112:
108:
100:
96:
82:
78:
75:
74:Biotechnology
72:
68:
65:
61:
57:
53:
50:
47:
42:
39:
36:
32:
28:
23:
20:Compugen Ltd.
1509:NICE Systems
1218:
1203:
1186:
1162:. Retrieved
1158:the original
1147:
1135:. Retrieved
1131:the original
1124:
1115:
1103:. Retrieved
1099:the original
1092:
1083:
1071:. Retrieved
1061:
1049:. Retrieved
1036:
1024:. Retrieved
1018:
1008:
999:
990:
981:
972:
963:
954:
945:
936:
927:
918:
909:
897:. Retrieved
882:
873:
861:. Retrieved
855:
845:
833:. Retrieved
823:
814:
806:
799:. Retrieved
792:
780:
768:. Retrieved
762:
752:
740:. Retrieved
717:
710:
698:. Retrieved
687:
679:
672:. Retrieved
665:
653:
641:. Retrieved
637:
627:
615:. Retrieved
592:
585:
573:. Retrieved
559:
550:
541:
532:
476:
467:
457:Drew Pardoll
450:
438:
425:
413:
400:
391:
379:
370:
345:
333:
309:
251:
248:
247:
239:
217:
195:
173:
171:53 thousand
110:Headquarters
34:Company type
1543:Electronics
1504:MIND C.T.I.
1251:SEC filings
1220:Red Herring
1164:13 December
1137:13 December
1105:15 December
1026:15 December
899:13 December
863:13 December
835:13 December
801:13 December
797:(in Hebrew)
770:15 December
742:13 December
700:13 December
674:13 December
670:(in Hebrew)
643:13 December
617:13 December
575:13 December
356:agriscience
280:Novartis AG
274:and on the
1673:Categories
1393:AudioCodes
1312:Healthcare
1200:"E=mc$ $ "
1094:Forbes.com
525:References
473:Management
288:Pfizer Inc
205:Net income
127:Key people
105:Amir Natan
1570:SolarEdge
1438:Radvision
1408:DSP Group
1324:BioLineRx
794:TheMarker
723:Dordrecht
638:Israel21c
504:In silico
441:MedImmune
326:'s elite
260:קומפיוג'ן
146:president
101:Eli Mintz
46:Traded as
1565:Orbotech
1489:CyberArk
1484:Cimatron
1457:Software
1448:RR Media
1388:Alvarion
1376:Networks
1335:Compugen
1329:BiondVax
569:Hoover's
493:See also
428:Bayer AG
382:Bayer AG
362:Pipeline
348:spun off
312:genomics
292:oncology
249:Compugen
136:chairman
70:Industry
1658:Isramco
1591:Arotech
1519:Radware
1319:Alcobra
1189:(126).
1073:May 15,
1051:May 15,
857:Haaretz
667:Haaretz
352:Evogene
306:History
225:Website
160:Revenue
98:Founder
88: (
80:Founded
62::
54::
1494:Jacada
1433:Radcom
1298:Nasdaq
1205:Forbes
1191:France
1126:Forbes
1020:Globes
764:Globes
733:
608:
571:. 2011
268:Israel
256:Hebrew
218:(2016)
196:(2016)
174:(2016)
148:&
120:Israel
52:Nasdaq
38:Public
1350:Pluri
1045:(PDF)
115:Holon
1550:CEVA
1166:2011
1139:2011
1107:2011
1075:2018
1053:2018
1028:2011
901:2011
865:2011
837:2011
803:2011
772:2011
744:2011
731:ISBN
702:2011
676:2011
645:2011
619:2011
606:ISBN
577:2011
298:and
286:and
252:Ltd.
232:.com
230:cgen
169:US$
90:1993
83:1993
64:CGEN
60:TASE
56:CGEN
1534:Wix
479:CEO
336:EST
324:IDF
150:CEO
1675::
1231:.
1217:.
1202:.
1185:.
1123:.
1091:.
1017:.
891:.
887:.
881:.
854:.
805:.
761:.
725::
721:.
678:.
636:.
600::
596:.
567:.
282:,
258::
118:,
1282:e
1275:t
1268:v
1223:.
1208:.
1168:.
1141:.
1109:.
1077:.
1055:.
1030:.
903:.
867:.
839:.
774:.
746:.
704:.
647:.
621:.
579:.
254:(
152:)
144:(
138:)
92:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
